
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
The authors outline stability studies designed to evaluate the effect of temperature excursions on product quality that may occur during distribution.
over 22 years ago
3M Drug Delivery Systemsover 22 years ago
AccuRateover 22 years ago
July 2004over 22 years ago
Investors Shy Away from Pharmaceutical Chemicalsover 22 years ago
In the Spotlight-July 2004over 22 years ago
Politics Versus Science in Biomedical Research and Development





